OncoMatch/Clinical Trials/NCT06688188

68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study

Is NCT06688188 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies 68Ga-JH12 for malignant neoplasm.

Early Phase 1RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT06688188Data as of Jun 2026Location: China

Treatment: 68Ga-JH12 — 68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

68Ga-JH12

Cancer type

Tumor Agnostic

Demographics

Ages ≤ 80

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06688188 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify